The Deutsche Krebsforschungszentrum (DKFZ) Heidelberg was founded as a non-profit organization and supraregional research center by the Land (state) Baden-Württemberg in 1964. More
The Pierre Fabre Group, the second-largest independent laboratory in France, employs about 9,300 people and achieved sales of 1.47 billion euros in 2004. More
• Address unmet medical needs in infectious diseases and cancer, using innovative therapeutic protein variants identified from a proprietary and original use of natural human genetic variability More
CollaGenex is developing dermatological applications of its proprietary IMPACS technology. Oracea (doxyxcycline, USP) 40 mg* was approved by the FDA on May 26, 2006. More
DFB, a specialty pharmaceutical company with expertise in liquid/semi-solid skin, soft tissue therapies, provides: branded products, outsourcing services, licensing opportunities More
BioVex : Developing a new class of vaccines to treat and prevent cancer - OncoVEX and ImmunoVEX, and a functional genomics platform for gene determination in the nervous system - NeuroVEX More
MedSource is a niche CRO focused on the Project Management and Monitoring of critical Phase I-IV studies in difficult therapeutics like Oncology, HIV, and Infectious disease. More